AC
BIIB icon

Avestar Capital’s Biogen BIIB Stock Holding History

Avestar Capital’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,000
Closed -$480K – 400
2021
Q4 		$480K Sell
2,000
-4,500
-69% -$1.16M 0.06% 264
2021
Q3 		$1.84M Buy
6,500
+3,000
+86% +$983K 0.24% 100
2021
Q2 		$1.21M Buy
+3,500
New +$1.06M 0.16% 154

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Avestar Capital's BIIB Position: Q2 2026 in Review

Avestar Capital reduced its Biogen (BIIB) stake by 6.5% in Q2 2026, selling an estimated $44.6K and leaving 3,371 shares worth $728K. The position accounts for 0.04% of the portfolio, ranked #300.

Avestar Capital first reported a position in BIIB in Q4 2017 and has held it in 35 quarters since. The position peaked at $852K in Q3 2018. 1,044 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Avestar Capital held 3,371 shares of Biogen worth $728K as of Q2 2026.
  • Avestar Capital sold 233 Biogen shares in Q2 2026, an estimated $44.6K.
  • Biogen made up 0.04% of Avestar Capital's portfolio in Q2 2026, its #300 holding.
  • Avestar Capital first reported a position in Biogen in Q4 2017 and has held it in 35 quarters since.
  • Avestar Capital's Biogen position peaked at $852K in Q3 2018.
  • 1,044 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Avestar Capital's 13F filing for Q2 2026, filed 29 Jul 2026.